KLK3 and prostate carcinoma: Prostate cancer incidence rates in Sweden are now comparable to rates in countries that had an early introduction of prostate-specific antigen (PSA) testing, while prostate cancer mortality rates are higher than in most other countries.1 With over 90 000 prevalent cases, the health burden and the costs on the healthcare system are substantial.